Drug Profile
Ompenaclid - Inspirna
Alternative Names: RGX-202; RGX-202-01Latest Information Update: 28 Apr 2024
Price :
$50
*
At a glance
- Originator Rgenix
- Developer Inspirna
- Class Antineoplastics; Guanidines; Propionic acids; Small molecules
- Mechanism of Action Creatine transporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- No development reported Biliary cancer; Gastric cancer; Intestinal cancer; Oesophageal cancer; Pancreatic cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Biliary-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Biliary-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (PO)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Colorectal-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (PO)